Your Questions About Carnitine

June 29, 2012

Daniel asks…

Is it safe to take L-Carnitine to help lose weight if im on a prescripted medicine which is accutane?

I wanna lose weight and the guys from gnc recommended LCarnitine since im sensitive to caffeine but they say take 1 capsule in the morning which is the same time i have to take my accutane medicine for my mild acne. I was just wondering if it is safe to mix the two together? seeing as carnitine is just an amino acid thin?? Help?

admin answers:

You’re better off without the accutane, under any circumstances. Just use warm water, mild soap, and a dilute lemon-rinse, three times a day. That’s the best way to make mild acne better.

Accutane is getting some horror stories lately. People’s skin can get trashed, years down the road.

Paul asks…

How much water should i use to dilute 1gram of Acetyl l-Carnitine powder before drinking?

No i dont want to see a dietician. I’m a pretty heavy trainer and and i want to know how much water to use for every gram of acetyl l carnitine???? or doesnt it matter?

admin answers:

I don’t think it really matters – use enough to mix it and chug it.

Mark asks…

How should Carnitine Deficiency be treated in infants?

My cousin’s daughter has been diagnosed with Acid Reflux disease, some muscle diseases that the doctors don’t know what they are yet and Carnitine Deficiency. She’s on some meds for these problems. She has a Mic button in her stomach to eat with because she doesn’t eat right. She throws up a lot and it comes out of her mic button as well. Can anyone tell me what the normal treatment for carnitine deficiency is??

admin answers:

I copy this abstract for you, from the UCSF, Children’s Hospital Central California, 9300 Valley Children’s Place, Madera, CA 93638, USA
Abstract Summary: Carnitine deficiency is a secondary complication of many inborn errors of metabolism. Pharmacological treatment with carnitine not only corrects the deficiency, it facilitates removal of accumulating toxic acyl intermediates and the generation of mitochondrial free coenzyme A (CoA). The United States Food and Drug Administration (US FDA) approved the use of carnitine for the treatment of inborn errors of metabolism in 1992. This approval was based on retrospective chart analysis of 90 patients, with 18 in the untreated cohort and 72 in the treated cohort. Efficacy was evaluated on the basis of clinical and biochemical findings. Compelling data included increased excretion of disease-specific acylcarnitine derivatives in a dose–response relationship, decreased levels of metabolites in the blood, and improved clinical status with decreased hospitalization frequency, improved growth and significantly lower mortality rates as compared to historical controls. Complications of carnitine treatment were few, with gastrointestinal disturbances and odour being the most frequent. No laboratory or clinical safety issues were identified. Intravenous carnitine preparations were also approved for treatment of secondary carnitine deficiency. Since only 25% of enteral carnitine is absorbed and gastrointestinal tolerance of high doses is poor, parenteral carnitine treatment is an appealing alternative therapeutic approach. In 7 patients treated long term with high-dose weekly to daily venous boluses of parenteral carnitine through a subcutaneous venous port, benefits included decreased frequency of decompensations, improved growth, improved muscle strength and decreased reliance on medical foods with liberalization of protein intake. Port infections were the most troubling complication. Theoretical concerns continue to be voiced that carnitine might result in fatal arrhythmias in patients with long-chain fat metabolism defects. No published clinical studies substantiate these concerns. Carnitine treatment of inborn errors of metabolism is a safe and integral part of the treatment regime for these disorders.
(This revised version was published online in August 2006 with corrections to the Cover Date.)

Hope this helps
matador 89

Powered by Yahoo! Answers

Tags: , , , , , , , , , ,

Leave a Reply

Your email address will not be published. Required fields are marked *